1. The Role of TAK1 in RANKL-Induced Osteoclastogenesis
   Wu Jianwei et al, 2022, Calcified Tissue International CrossRef
2. Inhibition of MEK/ERK upregulates GSH production and increases RANKL-induced osteoclast differentiation in RAW 264.7 cells
   Taiwo Samuel Agidigbi et al, 2020, Free Radical Research CrossRef
3. DAPT inhibits titanium particle‐induced osteolysis by suppressing the RANKL/Notch2 signaling pathway
   Xiang Wei et al, 2020, Journal of Biomedical Materials Research Part A CrossRef
4. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL‐induced osteoclastogenesis
   Xiao Chen et al, 2017, The FASEB Journal CrossRef
5. Small molecule inhibitor RepSox prevented ovariectomy‐induced osteoporosis by suppressing osteoclast differentiation and bone resorption
   Liangwei Mei et al, 2018, Journal of Cellular Physiology CrossRef
6. ERK Inhibition Increases RANKL-Induced Osteoclast Differentiation in RAW 264.7 Cells by Stimulating AMPK Activation and RANK Expression and Inhibiting Anti-Osteoclastogenic Factor Expression
   Eun-Bi Choi et al, 2022, International Journal of Molecular Sciences CrossRef
7. Astragaloside IV attenuates inflammatory injury and promotes odontoblastic differentiation in lipopolysaccharide‐stimulated MDPC‐23 cells and rat pulpitis
   Qun Ding et al, 2019, Journal of Oral Pathology & Medicine CrossRef
8. Tetracycline-grafted mPEG-PLGA micelles for bone-targeting and osteoporotic improvement
   Yunduan Que et al, 2022, Frontiers in Pharmacology CrossRef
9. Inhibitory effects of cycloastragenol on abdominal aortic aneurysm and its related mechanisms
   Yunxia Wang et al, 2019, British Journal of Pharmacology CrossRef
10. Astragaloside-IV induces the differentiation of bone marrow mesenchymal stem cells into osteoblasts throughNMUR2-mediated Wnt/β-catenin pathway
    Yujing Cao et al, 2023, Regenerative Medicine CrossRef
11. Astragaloside IV protects against iron loading‐induced abnormal differentiation of bone marrow mesenchymal stem cells (BMSCs)
    Hui Jin et al, 2021, FEBS Open Bio CrossRef
12. Systemic drugs that influence titanium implant osseointegration
    Dragos Apostu et al, 2017, Drug Metabolism Reviews CrossRef
13. IL-13 and IL-13Rα1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation
    Yanjie Zhang et al, 2018, Biochemical and Biophysical Research Communications CrossRef
14. Efficacy and Possible Mechanisms of Astragali Radix and its Ingredients in Animal Models of Osteoporosis: A Preclinical Review and Metaanalysis
    Ning Cao et al, 2024, Current Drug Targets CrossRef
15. Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats
    Yanhai Xi et al, 2022, Drug Delivery CrossRef
16. Astragaloside IV Alleviates Lipopolysaccharide-Induced Acute Kidney Injury Through Down-Regulating Cytokines, CCR5 and p-ERK, and Elevating Anti-Oxidative Ability
    Wei Zhou et al, 2017, Medical Science Monitor CrossRef
17. Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway
    Li‑Hua Guo et al, 2018, International Journal of Molecular Medicine CrossRef
18. Effect of Ishophloroglucin A Isolated from Ishige okamurae on In Vitro Osteoclastogenesis and Osteoblastogenesis
    Su-Hyeon Cho et al, 2023, Marine Drugs CrossRef
19. Multiple versus solitary giant cell lesions of the jaw: Similar or distinct entities?
    Willem H. Schreuder et al, 2021, Bone CrossRef